Genetic screens based on CRISPR-Cas9 have successfully identified several targets in AML, specifically MARCH5, which prevents apoptosis in AML and whose repression enhanced the efficacy of BCL2 inhibitors such as VEN (4), not only in established AML cell lines, but also in PDX models, which are considered to be the most faithful to the primary human disease. This evidence concerns the gene BCL2 and acute myeloid leukemia.